5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase.

Explore this paper's citation graph

Summary

Treatment of hepatoma cells with 5-aminoimidazole-4-carboxamide riboside (AICAR), an agent that activates AMP-activated protein kinase (AMPK), mimics the ability of insulin to repress PEPCK gene transcription and suggests activation of AMPK would inhibit hepatic gluconeogenesis in an insulin-independent manner and thus help to reverse the hyperglycemia associated with type 2 diabetes.

Type
article
Published
2000-06-01
Cited by
406
References
67
Access
Open access

Keywords

Gluconeogenesis, AMPK, Insulin, Insulin receptor, Biology

References

Cited by

Related papers